Shares in Belgian biotech Oxurion are taking a hammering this morning after it reported that one of its drugs for diabetic eye disease had failed a phase 2 trial and will be terminated.
Apellis' chances of getting regulatory approval for pegcetacoplan, its drug candidate for sight-robbing disease geographic atrophy (GA), may have been heightened by new follow-up data from
The FDA has approved Roche's much-anticipated faricimab for two major causes of blindness, setting up a market clash with Bayer and Regeneron's market leading drug Eylea.